Drug Trial Radar · NCT04811716
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 29, 2021
Primary completion
Oct 25, 2022
Study completion Oct 18, 2023
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (OLTP) The secondary objectives of the study are: * To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of total complement hemolysis activity (CH50) * To evaluate the effect of the combination treatment on hemoglobin levels * To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements * To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life * To assess the concentrations of total pozelimab in serum and total complement component (C) 5 and cemdisiran in plasma * To assess immunogenicity to pozelimab and cemdisiran * To evaluate the long-term safety and efficacy of pozelimab and cemdisiran in an optional open-label extension period (OLEP) * To assess safety after treatment intensification with pozelimab and cemdisiran
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
PozelimabDrug
Administered Sub-cutaneous (SC) per protocol
CemdisiranDrug
Administered SC per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Through Week 28
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
Prince of Wales Hospital
Hong Kong, New Territories, Hong Kong
D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet
Budapest, Nagyvárad Tér 1, Hungary
Hospital Miri
Miri, Sarawak, Malaysia
Hospital Sibu
Sibu, Sarawak, Malaysia
Hospital Sultanah Nur Zahirah
Kuala Terengganu, Terengganu, Malaysia
Pusan National University Hospital
Busan, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University College of Medicine, Severance Hospital
Seoul, South Korea
Ewha Womans University Medical Centre
Seoul, South Korea
Samsung Medical Center
Seoul, Seoul Teugbyeolsi, South Korea
National Taiwan University Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital
Taoyuan City, Taiwan
St. James's University Hospital
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.